Related Experiment Videos

Apoptosis and chemoresistance in human ovarian cancer: is Xiap a determinant?

J Li1, H Sasaki, Y L Sheng

  • 1Department of Obstetrics and Gynaecology and Department of Cellular and Molecular Medicine, University of Ottawa, Loeb Health Research Institute, The Ottawa Hospital (Civic Campus), Canada.

Insights

Cisplatin chemotherapy triggers apoptosis in ovarian cancer by altering cell death and survival gene expression. Targeting Xiap (X-linked inhibitor of apoptosis protein) may overcome chemoresistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Cisplatin is a key chemotherapy agent for epithelial ovarian cancer (EOC).
  • Chemoresistance remains a significant challenge in EOC treatment.
  • The balance between cell death and cell survival genes influences treatment response.

Purpose of the Study:

  • To investigate the molecular mechanisms underlying cisplatin-induced apoptosis in EOC cells.
  • To identify key regulatory genes involved in chemoresistance.
  • To explore Xiap as a potential therapeutic target for overcoming cisplatin resistance.

Main Methods:

  • Analysis of gene expression changes in EOC cells treated with cisplatin.
  • Focus on the roles of Xiap (X-linked inhibitor of apoptosis protein), Fas/FasL, caspase-3, MDM2, and FAK.
  • Exploration of gene therapy strategies involving Xiap antisense and P53.

Main Results:

  • Cisplatin treatment suppresses Xiap expression and upregulates the Fas/FasL system in EOC cells.
  • These changes activate caspase-3 and lead to cleavage of MDM2 and FAK.
  • Imbalance in these gene expressions favors chemoresistance.

Conclusions:

  • Suppressed Xiap and activated Fas/FasL are crucial in cisplatin-induced apoptosis.
  • Xiap dysregulation contributes to chemoresistance in EOC.
  • Targeting Xiap, potentially with P53 modulation, offers a novel therapeutic strategy for chemoresistant ovarian cancer.

Related Concept Videos